Updates On Invokana Lawsuit

A lawsuit has been filed against Janssen Pharmaceuticals, a manufacturing company under Johnson and Johnson. Last year alone, the company netted a profit of almost 1$ billion. Judicial Panel on Multi district Litigation ordered the consolidation of Invokana lawsuits regarding diabetic and kidney damage lawsuits to New Jersey. A case management conference has been held where plaintiffs, defendants and judges discussed the way forward. The manufacturer has recently filled to move over 100 cases in Pennsylvania to New Jersey. Plaintiffs are fighting for the cases to remaining in PA. They argue that the move will go against the provisions under Class Action Fairness Act.

Mobilization

The panel has transferred almost 100 Invokana and Invokamet suits from districts in Missouri, Virginia, Kentucky, West Virginia and Minnesota to New Jersey under U.S district judge, Brian R. Martinotti. This was induced by Janssen Pharmaceuticals having it headquarters in New Jersey. Apparently, many witnesses and relevant documents are found in this district. A good number of Invokana cases have been filed here. The JPMDL ruling indicated that Invokana cases had common queries of facts. Therefore, it was more convenient to have them centralized.

The first case management conference was held earlier on January which brought together plaintiffs and defendants. Discussions were held concerning the current status, organizational status, possible amendments for pleads and a discovery plan for preparing cases for trial. The judge was expected to provide plaintiffs with different leadership roles. Janssen Pharmaceuticals has filled a new case requiring all cases from PA to be transferred to New Jersey. Plaintiffs are fighting the transfer of over 100 well-consolidated cases.

Concerns

The common issues raised are whether Invokana causes kidney injury and diabetic ketoacidiosis. Other questions delve into the development process, promotion, testing, regulation and branding of the drug. Plaintiffs also reported that Invokana caused them to suffer stroke and blood clots.

FDA approved the drug in 2013 but recalled the approval 2 years later demanding the addition of a ketoacidosis warning label. Health risks continue accumulating until FDA issued a warning in 2015 regarding the potential of Invokana to cause serious blood and kidney infections. A year later the regulatory company reported pancreatic infections among drug users. Apparently, Invokana caused pancreatic inflammation and swelling. The safety warning issued in 2015 also indicated that Invokana can increase the risk of bone fracture.

Conclusion

The next step of this medical law suit involves court proceedings before Judge Martinotti. Lawyers are now evaluating whether users may be entitled to compensation using a product liability lawsuit. Users are urged to submit all potential cases for review by lawyers. New developments are found in the Invokana lawsuit update section at http://invokana-lawsuit.net/. In case you have any complications contact their lawyers for an evaluation.